Blog

Careers

Advertise

Contact

logo
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • Events
    • National Pharmacy Forum 2021
    • Past Events
  • CHeS
    • CHeS Total Visibility Project
    • CHeS Membership
    • CHeS Resources
  • Issues
  • Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • Small Supplier Portal
    • Congressional Resources
    • COVID-19 Recommendations
  • News
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • Events
    • National Pharmacy Forum 2021
    • Past Events
  • CHeS
    • CHeS Total Visibility Project
    • CHeS Membership
    • CHeS Resources
  • Issues
  • Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • Small Supplier Portal
    • Congressional Resources
    • COVID-19 Recommendations
  • News

Comments of the Healthcare Supply Chain Association (HSCA) on Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020

October 15, 2019 by Brigid Hasson 2019 Press Releases 0 comments

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments on the U.S. Drug Enforcement Administration’s (DEA or Agency) proposed aggregate production quotas for Schedule I and II controlled substances. HSCA supports DEA’s efforts to support interagency collaboration around controlling opioid diversion. We are concerned, however, that absent differentiation of injectable opioids from solid dosage form for purposes of the rule, these changes to aggregate production quotas could lead to injectable narcotic shortages that threaten patient care.

Click here for the full comments.

Prev
Next

Related Posts

Group Comment Letter to FDA on Clinical Immunogenicity Considerations from Biosimilar and Interchangeable Insulin Products
January 28, 2020

Dear Commissioner Hahn, The undersigned groups share the Food and Drug...

Learn more
HSCA Applauds FDA for Releasing New Data to Enable Generic Competition
June 19, 2019

Washington, DC (June 19, 2019) – Healthcare Supply Chain Association (HSCA)...

Learn more
Comments of the Healthcare Supply Chain Association (HSCA) on FDA Request for Comments on Ethylene Oxide Sterilization of Medical Devices
December 12, 2019

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...

Learn more
HSCA CEO to Lead Panel Discussion on Innovation at AdvaMed’s MedTech Conference
September 23, 2019

Washington, DC (September 23, 2019) – The Healthcare Supply Chain...

Learn more

Our Office

Healthcare Supply Chain Association
1341 G Street NW Suite 600
Washington, DC 20005

Phone: 202.629.5833
Fax: 202.466.9666
Email: info@supplychainassociation.org

LATEST NEWS

  • HSCA Statement on President Biden’s Executive Order on America’s Supply Chains
    February 25, 2021
  • HSCA Comments to FDA Regarding FDA’s List of Public Health Focused Essential Medicines
    February 5, 2021